James W. Vardiman

Q: What Schools Are Affiliated With James W. Vardiman

James W. Vardiman is affiliated with the following schools: Ohio State University, Stanford University, University of Chicago

James W. Vardiman's AcademicInfluence.com Rankings

James W. Vardiman

Medical

#2028

World Rank

#2421

Historical Rank

Hematology

#27

World Rank

#30

Historical Rank

Oncology

#109

World Rank

#113

Historical Rank

medical Degrees

James W. Vardiman

Philosophy

#5970

World Rank

#8919

Historical Rank

Logic

#3171

World Rank

#4291

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is James W. Vardiman Influential?

(Suggest an Edit or Addition)

(See a Problem?)

James W. Vardiman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. (2016) (6707)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. (2009) (4395)
The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. (1999) (3234)
The World Health Organization (WHO) classification of the myeloid neoplasms. (2002) (2183)
World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. (1999) (1331)
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms (2008) (1011)
Diagnostic criteria and classification of mastocytosis: a consensus proposal. (2001) (1010)
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. (2007) (893)
Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. (1986) (681)
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. (2001) (678)
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. (2003) (650)
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). (2003) (598)
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. (2006) (508)
Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. (1983) (489)
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. (2008) (487)
Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. (1981) (444)
Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. (1984) (423)
The World Health Organization Classification of Hematological Malignancies Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997 (2000) (404)
The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. (2000) (346)
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. (2005) (335)
Lymphoma classification--from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms. (2000) (328)
Burkitt's lymphoma: a single disease with multiple variants. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. (1999) (324)
THE WORLD HEALTH ORGANIZATION CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES REPORT OF THE CLINICAL ADVISORY COMMITTEE MEETING (2000) (322)
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. (2006) (317)
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). (2006) (302)
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). (2007) (297)
Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model (1997) (296)
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. (2003) (250)
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. (2005) (249)
The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. (2010) (244)
Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. (1987) (236)
Acute myeloid leukaemia with recurrent genetic abnormalities. . (2001) (230)
The 2008 World Health Organization classification system for myeloproliferative neoplasms (2009) (216)
Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. (1996) (207)
Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis. (1986) (203)
Pomalidomide is active in the treatment of anemia associated with myelofibrosis. (2009) (198)
Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes (1986) (198)
Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. (1986) (196)
Myelodysplastic syndromes. (2009) (193)
Morphology in Ki‐1 (CD30)‐Positive Non Hodgkin's Lymphoma Is Correlated with Clinical Features and the Presence of a Unique Chromosomal Abnormality, t(2;5)(p23;q35) (1990) (188)
"Microgranular" acute promyelocytic leukemia: a distinct clinical, ultrastructural, and cytogenetic entity. (1980) (181)
Nonrandom chromosomal abnormalities in acute nonlymphocytic leukemia in patients treated for Hodgkin disease and non-Hodgkin lymphomas (1977) (179)
The 2008 Revision of the WHO Classification of Myeloid Neoplasms and Acute Leukemia : Rationale and Important Changes (2009) (177)
The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. (1989) (176)
Detection of trisomy 12 in chronic lymphocytic leukemia by fluorescence in situ hybridization to interphase cells: a simple and sensitive method. (1992) (173)
Treatment of hairy cell leukemia with recombinant alpha 2 interferon. (1985) (171)
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. (2004) (166)
Correlation of clinical findings with quinacrine-banded chromosomes in 90 adults with acute nonlymphocytic leukemia: an eight-year study (1970-1977). (1978) (165)
Acute leukaemias of ambiguous lineage. . (2001) (159)
Associations between morphology, karyotype, and clinical features in myeloid leukemias. (1987) (158)
Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. (1993) (158)
Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. (1983) (156)
Further evidence for a non‐random chromosomal abnormality in acute promyelocytic leukemia (1977) (151)
miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia (2012) (148)
Detection of numerical chromosomal abnormalities in neoplastic hematopoietic cells by in situ hybridization with a chromosome-specific probe. (1990) (139)
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. (2005) (137)
Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. (2006) (136)
Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics (2009) (129)
Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. (2001) (122)
Evolution of karyotypes in acute nonlymphocytic leukemia. (1979) (121)
Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. (1995) (120)
Correlation of occupation and karyotype in adults with acute nonlymphocytic leukemia (1982) (116)
Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11) (1990) (116)
t(3;21)(q26;q22): A Recurring Chromosomal Abnormality in Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia (1990) (116)
RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia (2018) (111)
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. (2010) (111)
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia (2013) (109)
Clinical, morphologic, and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia. (1992) (108)
The predictive value of initial cytogenetic studies in 148 adults with acute nonlymphocytic leukemia: a 12-year study (1970-1982). (1983) (108)
Increased incidence of second neoplasms in patients treated with interferon alpha 2b for hairy cell leukemia: a clinicopathologic assessment. (1994) (107)
Philadelphia chromosome‐negative chronic myelogenous leukaemia: a morphological reassessment (1985) (107)
Increased numbers of marrow basophils may be associated with a t(6;9) in ANLL (1985) (107)
Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. (2004) (105)
Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome. (1996) (101)
Acute nonlymphocytic leukemia in adults: correlations with Q-banded chromosomes. (1976) (94)
Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. (2007) (93)
Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. (2007) (92)
Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma (2004) (92)
Direct correlation of cytogenetic findings with cell morphology using in situ hybridization: an analysis of suspicious cells in bone marrow specimens of two patients completing therapy for acute lymphoblastic leukemia. (1991) (88)
Dysmyelopoietic syndrome: sequential clinical and cytogenetic studies. (1980) (87)
Chromosome abnormalities in B cell chronic lymphocytic leukemia and their clinical correlations. (1989) (87)
Disseminated atypical mycobacterial infection in patients with hairy cell leukemia. (1986) (85)
Partial deletion of long arm of chromosome 17: a specific abnormality in acute promyelocytic leukemia? (1976) (85)
Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion (1993) (84)
Correlation between cell morphology and expression of the AML1/ETO chimeric transcript in patients with acute myeloid leukemia without the t(8;21). (1994) (84)
Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine. (1988) (82)
Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology. (2017) (80)
Mesocolic lymph node histology is an important prognostic indicator for patients with carcinoma of the sigmoid colon: An immunomorphologic study (1975) (77)
Additional cytogenetic abnormalities in adults with Philadelphia chromosome‐positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B (2004) (76)
Chronic myelogenous leukemia, BCR-ABL1+. (2009) (75)
Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables. (1988) (75)
Acute Myeloid Leukemia With Myelodysplasia-Related Changes. (2015) (74)
Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. (1988) (73)
A subset of Rosai-Dorfman disease exhibits features of IgG4-related disease. (2013) (73)
Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes. (1993) (72)
A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes (2003) (70)
A 14;19 TRANSLOCATION IN B‐CELL CHRONIC LYMPHOCYTIC LEUKEMIA: A NEW RECURRING CHROMOSOME ABERRATION (1985) (69)
Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes. (2006) (68)
Interphase cytogenetic analysis detects minimal residual disease in a case of acute lymphoblastic leukemia and resolves the question of origin of relapse after allogeneic bone marrow transplantation. (1991) (67)
Hairy Cell Leukaemia: Evidence for the Existence of a Spectrum of Functional Characteristics (1978) (66)
Chromosomal loss and deletion are the most common mechanisms for loss of heterozygosity from chromosomes 5 and 7 in malignant myeloid disorders. (1992) (65)
Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia. (1996) (64)
Acute nonlymphocytic leukemia in malignant lymphoma. A morphologic study (1978) (62)
Codeletion of CDKN2 and MTAP genes in a subset of non‐Hodgkin's lymphoma may be associated with histologic transformation from low‐grade to diffuse large‐cell lymphoma (1998) (60)
A morphologic and cytochemical study of acute myelomonocytic leukemia with abnormal marrow eosinophils associated with inv(16)(p13q22). (1984) (60)
Hypergranular promyelocytic leukemia (APL): cytogenetic and ultrastructural specificity. (1978) (60)
Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. (1986) (57)
Karyotypic patterns and their clinical significance in polycythemia vera (1981) (57)
Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. (2002) (57)
World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants. (2011) (57)
THE UPDATED WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES The 2016 revision to the World Health Organization classi ﬁ cation of myeloid neoplasms and acute leukemia (2016) (56)
Correlation of occupation and karyotype in adults with acute nonlymphocytic leukemia. (1982) (56)
Hematopathologic findings in the myeloproliferative disorders. (1995) (55)
Cat Scratch Disease: Identification of Bacteria in Seven Cases of Lymphadenitis (1986) (54)
Durability of responses to interferon alfa-2b in advanced hairy cell leukemia. (1987) (54)
Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study (2014) (53)
Acute myeloid leukaemia not otherwise categorised. . (2001) (51)
The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia. (1995) (48)
Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. (2006) (47)
Multiple hemopoietic lineages are found after stimulation of mouse bone marrow precursor cells with interleukin 3. (1984) (47)
Autopsy findings in hairy cell leukemia. (1984) (47)
Haematopoietic malignancies in zoo animals. (1992) (46)
MPN-associated myelofibrosis (MPN-MF). (2011) (46)
changes of myeloid neoplasms and acute leukemia: rationale and important The 2008 revision of the World Health Organization (WHO) classification (2013) (43)
The classification of MDS: from FAB to WHO and beyond. (2012) (43)
Myelodysplastic/myeloproliferative diseases. (2004) (42)
t(3;21)(q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia. (1990) (40)
The diagnostic interface between histology and molecular tests in myeloproliferative disorders (2007) (39)
Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia [see comments] (1990) (38)
Myeloid leukemia after hematotoxins. (1996) (38)
Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice. (2015) (37)
Myelodysplastic syndromes. (2004) (37)
Hodgkin's disease associated with chronic lymphocytic leukemia. Eight additional cases, including two of the nodular lymphocyte predominant type. (1995) (37)
Clinical and cytogenetic responses to granulocyte-macrophage colony-stimulating factor in therapy-related myelodysplasia. (1992) (36)
Myelodysplastic syndromes: introduction. (2001) (36)
Trisomy 6: a recurring cytogenetic abnormality associated with marrow hypoplasia [letter] (1991) (36)
Morphologic and cytochemical observations on the overt leukemic phase of therapy-related leukemia. (1983) (36)
Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802. (2005) (36)
Recurring diagnostic problems in the pathology of the myelodysplastic syndromes. (1996) (36)
Changes in Peripheral Blood and Bone Marrow Specimens Following Therapy with Recombinant Alpha2 Interferon for Hairy Cell Leukemia (1986) (35)
Cytogenetic and ultrastructural features of de novo acute promyelocytic leukemia; The university of Chicago experience (1973–1978)☆ (1979) (32)
Prognostic variables in hairy cell leukemia after splenectomy as initial therapy (1988) (31)
Chlorambucil therapy of twenty-four postsplenectomy patients with progressive hairy cell leukemia. (1984) (31)
Acute myeloid leukaemia: Introduction. . (2001) (30)
Low-dose interferon alfa-2b in the treatment of hairy cell leukemia. (1989) (29)
Evolution of karyotypes in philadelphia (Ph1) chromosome‐negative chronic myelogenous leukemia (1979) (29)
Hairy cell leukemia. An autopsy study (1979) (28)
Bone marrow fibrosis and diagnosis of essential thrombocythemia. (2009) (28)
Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion. (1993) (27)
Myelodysplastic syndromes, chronic myeloproliferative diseases, and myelodysplastic/myeloproliferative diseases. (2003) (27)
Myelodysplastic syndromes: from French-American-British to World Health Organization: a commentary. (2002) (26)
A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients < 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808. (2005) (25)
Acute leukemia after treatment of lymphoma. (1977) (25)
Issues in the pathology of the myelodysplastic syndromes. (1992) (24)
The role of interferon in the treatment of hairy cell leukemia. (1986) (23)
Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia. (1990) (21)
The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failure (1991) (21)
Acute panmyelosis with myelofibrosis: a clinicopathological study on 46 patients including histochemistry of bone marrow biopsies and follow-up (2004) (21)
Development of dysmyelopoietic syndrome in a hairy cell leukemia patient treated with chlorambucil: cytogenetic and morphologic evaluation. (1983) (21)
ACUTE MYELOID LEUKAEMIA FOLLOWING INTERFERON‐ALFA TREATMENT OF HAIRY CELL LEUKAEMIA (1993) (20)
Human T-cell lymphoma with suppressor effects on the mixed lymphocyte reaction (MLR). I. Morphological and cytogenetic analysis (1981) (20)
Biological significance of cell cycle kinetics in 128 standard risk newly diagnosed patients with acute myelocytic leukaemia (1991) (20)
Evaluation of Leu-M5 (CD11c) in hairy cell leukemia by the alkaline phosphatase anti-alkaline phosphatase technique. (1988) (20)
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies. (1994) (19)
Megakaryocytic blast crisis as a presenting manifestation of chronic myeloid leukemia. (2008) (19)
Myelodysplastic/myeloproliferative neoplasms. (2011) (19)
Sequential treatment of hairy cell leukemia: a new role for interferon. (1986) (18)
Burkitt’s Lymphoma: A Single Disease With Multiple Variants (1999) (18)
Trisomy 6: a recurring cytogenetic abnormality associated with marrow hypoplasia. (1991) (18)
Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461. (2004) (17)
Hairy cell leukemia in father and son (1981) (17)
Acute myeloid leukaemia with multilineage dysplasia. . (2001) (16)
Correlation Between Morphology and Karotype (1984) (16)
HTLV‐I Sequence in Lymphoproliferative Disorders (1993) (16)
Cytochemistry of hairy cells (1980) (15)
Refractory cytopenia with multilineage dysplasia (2001) (15)
Hairy-cell leukemia. Morphologic, cytochemical, and immunologic features. (1988) (15)
Acute myeloid leukemia with expanded erythropoiesis (2011) (15)
The new World Health Organization classification of myeloid neoplasms: Q&A with James W. Vardiman, MD. (2003) (15)
PLZF staining identifies peripheral T-cell lymphomas derived from innate-like T-cells with TRAV1-2-TRAJ33 TCR-α rearrangement. (2014) (14)
Expression of the IFNα receptor in hairy cell leukaemia (1992) (14)
Survival Experience of 195 Patients with Hairy Cell Leukemia Treated in a Multi-Institutional Study with Interferon-Alfa 2B. (1991) (14)
New entities, issues, and controversies in the classification of malignant lymphoma. (1998) (14)
Morphologic bone marrow changes in patients with posttransplantation lymphoproliferative disorders. (1998) (13)
The histopathologic diagnosis and subclassification of Hodgkin's disease. (1989) (12)
Myelodysplastic syndrome with isolated del(5q) chromosome abnormality (2003) (12)
Refractory anaemia with ringed sideroblasts (2001) (12)
Independent Validation of Prognostic Relevance of a Previously Reported Gene-Expression Signature in Acute Myeloid Leukemia (AML) with Normal Cytogenetics (NC): A Cancer and Leukemia Group B (CALGB) Study. (2005) (11)
Clinical and prognostic significance of in vivo differentiation in acute myeloid leukemia (1993) (11)
Acute myeloid leukaemias and myelodysplastic syndromes, therapy related. (2001) (11)
T-cell-rich B-cell lymphoma of the spleen. (1994) (11)
Genome-wide profiling reveals epigenetic inactivation of the PU.1 pathway by histone H3 lysine 27 trimethylation in cytogenetically normal myelodysplastic syndrome (2013) (11)
Author Correction: RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia (2018) (10)
Human T-cell lymphoma with suppressor effects on the mixed lymphocyte reaction (MLR). I. Morphological and cytogenetic analysis. (1981) (10)
The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cells (2008) (10)
CD5+, CD11c+, CD20+ hairy cell leukemia [letter; comment] (1991) (9)
Pomalidomide Therapy in Anemic Patients with Myelofibrosis: Results from a Phase-2 Randomized Multicenter Study (2008) (9)
Changes in peripheral blood and bone marrow specimens following therapy with recombinant alpha 2 interferon for hairy cell leukemia. (1986) (9)
Group B studies A comparison of Children's Cancer Group and Cancer and Leukemia acute lymphoblastic leukemia treated on cooperative group protocols? What determines the outcomes for adolescents and young adults with (2011) (9)
Sinus histiocytosis with massive lymphadenopathy: response to cyclophosphamide therapy. (1984) (9)
Multiple histologic subtypes of non‐Hodgkin's lymphoma: Clinical and pathologic features (1981) (8)
Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan (2009) (7)
Changes in peripheral blood and bone marrow specimens during and after alpha 2b-interferon therapy for hairy cell leukemia. (1987) (7)
Prognostic significance of immunologic phenotype in hairy cell leukemia: does it exist? (1985) (6)
Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide (2020) (6)
Hypercalcemia and lytic bone lesions in a patient with B-cell non-Hodgkin's lymphoma. (1984) (6)
Refractory anaemia with excess blasts. (2001) (6)
NEUTROPHILIC LEUCOCYTE ALKALINE PHOSPHATASE SCORES IN HAIRY CELL LEUKAEMIA: CYTOCHEMICAL, FUNCTIONAL, AND CLINICAL CORRELATIONS (1979) (6)
Ultrastructural characterization of de novo and secondary leukemias (1982) (5)
Prediction of response to G-CSF and epo treatment for the anaemia of myelodysplastic syndromes (MDS) (1994) (5)
The Conundrum of Diagnosing Cutaneous Composite Lymphoma in the Molecular Age. (2019) (5)
Complex rearrangement of the T cell receptor in large granular lymphocytosis associated with myeloid suppression. (1990) (5)
Response: The 2008 World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: a paradigm of effective collaboration among clinicians, pathologists, and scientists (2008) (5)
Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues : Report of the Clinical Advisory Committee Meeting — Airlie House , Virginia , November 1997 By (1999) (5)
Pre-Treatment Cytogenetics Predict Complete Remission and Long-Term Outcome in Patients (Pts) ≥60 Years with Acute Myeloid Leukemia (AML): Results from Cancer and Leukemia Group B (CALGB) 8461. (2004) (4)
Expression of the IFN alpha receptor in hairy cell leukaemia. (1992) (4)
Extramedullary hematopoiesis. (1984) (3)
Diagnosis and Classification of the BCR-ABL1-Negative Myeloproliferative Neoplasms (2011) (3)
Familial Lymphoproliferative Disorders with Chromosomal Fragile Site Analysis. (1991) (3)
CD5+, CD11c+, CD20+ hairy cell leukemia. (1991) (2)
Genomic DNA Copy Number Alterations Present in AML Bone Marrow Samples with Normal Cytogenetics. (2004) (2)
Factors considered in the 2008 WHO classification of myeloid neoplasms and acute leukemias (2010) (2)
A recurring chromosome rearrangement, dic(16;22), in acute nonlymphocytic leukemia. (1988) (2)
Fourth International Workshop on Chromosomes in Leukemia 1982: Correlation between morphology and karyotype. (1984) (2)
Identical Novel C-Kit Transcripts in Two Patients with Mast Cell Leukemia. (2004) (2)
Overexpression of the ERG Gene Is an Adverse Prognostic Factor in Acute Myeloid Leukemia (AML) with Normal Cytogenetics (NC): A Cancer and Leukemia Group B Study (CALGB). (2005) (2)
Laboratory Medicine: Hematology (1982) (2)
Features of Therapy-Related Leukemia and their Comparison with Leukemia de Novo and with the Blast Phase of Chronic Granulocytic Leukemia (1984) (2)
Publisher Correction: miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia (2018) (2)
Granulocyte colony stimulating factor plus erythropoietin for the maintenance treatment of the anemia of myelodysplastic syndromes (1994) (2)
Nuclear FOXO3a Expression is A Frequent Occurrence in T-cell lymphomas (2013) (1)
Myelodysplastic Syndrome: Myelodysplastic Syndrome Associated with Isolated del(5q)Chromosome Abnormality ('5q- Syndrome') (2001) (1)
Early allogeneic transplantation for adults with de novo acute myeloid leukemia presenting with t(6;11)(q27;q23): Results from CALGB 8461. (2004) (1)
Myelodysplastic Syndrome: Refractory Anemia with Ringed Sideroblasts (RARS) (2001) (1)
Evolution of Karyotypes in Acute Nonlymphocytic Leukemia 1 (2006) (1)
OF DISEASE Myelodysplastic Syndromes (2009) (1)
Acute Leukemias and Myeloid Disorders (1997) (1)
Myelodysplastic syndromes associated with isolated del(5q) chromosome abnormality ("5q- syndrome"). . (2001) (1)
Clinicopathologic Characterization of Acute Myeloid Leukemia and Myelodysplastic Syndrome with Inv(3)(q21q26.2)/t(3;3)(q21;q26.2) Reveals That Complex Karyotype but Not Blast Percentage Is Associated with Poor Survival; A Bone Marrow Pathology Group Study (2012) (1)
Bromodomain and Extra-Terminal Motif Proteins (BETs) Mediate 5-Azacitidine Resistance in Myeloid Leukemia through Recruitment of an Active RNA Polymerase II Complex (2016) (1)
Principles of Classification of Myeloid Neoplasms (2011) (1)
Treatment of the 5 q – Syndrome Pierre Fenaux and Charikleia Kelaidi Myelodysplastic Syndromes (2006) (1)
Sequential Phase II Studies of Flavopiridol by 72-Hour Continuous Infusion and 1-Hour Intravenous Bolus for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia: Results from CALGB Study 19805. (2004) (1)
Author Correction: RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia (2018) (0)
Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children abnormalities of chromosomes 5 and 7 are common (1991) (0)
17 IDENTIFYING DISTINCT DIFFERENTIATION/LINEAGE-SPECIFIC DRUG-SENSITIVE CHROMATIN STRUCTURE AND THE UNDERLYING NOVEL MUTATIONS IN MDS AND LEUKEMIAS (2015) (0)
expert panel primary myelofibrosis: recommendations from an ad hoc international diagnostic criteria for polycythemia vera, essential thrombocythemia, and Proposals and rationale for revision of the World Health Organization (2013) (0)
Epidemiology and etiology (2003) (0)
combination with erythropoietin (see comments) recombinant human granulocyte colony-stimulating factor in Treatment of the anemia of myelodysplastic syndromes using (2011) (0)
Group B Study leukemia patients with normal cytogenetics: a Cancer and Leukemia BAALC expression predicts clinical outcome of de novo acute myeloid (2013) (0)
P-007 Novel epigenetic and genetic alterations in cytogenetically normal refractory cytopenia with multilineage dysplasia and chronic myelomonocytic leukemia (2013) (0)
Abstract 4470: RNA m5C methyltransferases and hnRNPK mediate disease-associated chromatin structure and drug resistance in leukemia (2017) (0)
A Novel Epigenetic Mechanism in the Pathogenesis of Myelodysplastic Syndrome (MDS) (2011) (0)
Correlations Among Morphology, Karyotypic Abnormalities, and Clinical Features in Myeloid Leukemia (1990) (0)
41 Profiling and characterizing aberrant DNA and histone methylations of lineage-determining factor encoding genes RUNX1, SPIB and SPI1 in myelodysplastic syndrome (2011) (0)
Myeloid Neoplasms. Myelodysplastic Syndrome: Refractory Ctyopenia with Multilineage Dysplasia (2001) (0)
Localization of Rheumatoid Factor by indirect Immunofluorescence (1972) (0)
Human T-Cell Lymphoma With Suppressor Effects on the Mixed Lymphocyte Reaction ( MLR ) (2005) (0)
Identifying chromatin structures and the underlying novel mutations that predict therapeutic responses to epigenetic drugs in MDS and AML (2016) (0)
Diagnosis of hairy cell leukemia (2003) (0)
PLZF Staining Identifies Peripheral T-Cell Lymphomas Derived From Non-Conventional T-Cells With Limited α-Chain Diversity (2013) (0)
Comparison of four categorized risk scoring systems for analyzing outcome in advanced MDS (1994) (0)
Novel C-KIT Transcripts Identified in Mast Cell Leukemia: An Update of the Full Transcript and It’s Distribution. (2007) (0)
Disease-Associated Chromatin Conformation and Therapeutic Implications In Leukemia (2013) (0)
A tribute to Dr. Henry Rappaport. (1993) (0)
Can multiple myeloma become a curable disease (2011) (0)
Erratum: Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia (Cancer (2013) 119 (90-8)) (2014) (0)
WHO'S NEXT? THE WHO CLASSIFICATION OF MYELOID NEOPLASMS (2010) (0)
16 – WHO Classification of Hematologic Malignancies (2014) (0)
Multiple Hemoopoietic Lineages Are Found After Stimulation of Mouse Bone Marrow Precursor Cells With Interleulin 3 (2007) (0)
complete responses to high-dose cytarabine Short remission durations in therapy-related leukemia despite cytogenetic (2011) (0)
RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia (2018) (0)
Nonlymphoblastic T‐cell lymphoma in children (1987) (0)
CD5+, CD11C+, HAIRY CELL LEUKEMIA. RESPONSE (1991) (0)
Diagnosis of Myelodysplastic Syndromes: Criteria and Challenges (2008) (0)
Epigenetic Modifying Drugs Inhibit MDS/AML Cell Growth through Selective Disruption of the Interactions Between Lineage-Determining Transcription Factors and DNA/Histone Modifiers (2015) (0)
Classification of the Myeloid Neoplasms ( Running title : Myeloid neoplasms ) (2002) (0)
ultrastructural, and cytogenetic entity "Microgranular" acute promyelocytic leukemia: a distinct clinical, (2011) (0)
erythropoietin: evidence for in vivo synergy with recombinant human granulocyte colony-stimulating factor and Maintenance treatment of the anemia of myelodysplastic syndromes (2011) (0)
RNA/HnRNPK and BRD4/BET Mediate 5-Azacytidine (5-AZA) Action and Resistance in MDS/AML (2017) (0)
Characterizing Epigenetic Patterns and Pharmacologic Responses in Myelodysplastic Neoplasms (2012) (0)
Book Reviews (2002) (0)
arising in the setting of severe congenital neutropenia Distinct patterns of mutations occurring in de novo AML versus AML (2013) (0)
Fa m ilia1 Chr Lymphoproliferati osomal Fragile Sit born ve Disorders with e Analysis (1991) (0)
Myelodysplastic syndromes, unclassifiable. . (2001) (0)
t(8;21) Acute Myeloid Leukemia (AML) Differs from inv(16) AML in Pretreatment Characteristics, Outcome and Prognostic Factors Predicting Outcome: A Cancer and Leukemia Group B (CALGB) Study. (2004) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With James W. Vardiman?

James W. Vardiman is affiliated with the following schools:

James W. Vardiman's Academic­Influence.com Rankings

Why Is James W. Vardiman Influential?

James W. Vardiman's Published Works

Published Works

What Schools Are Affiliated With James W. Vardiman?

James W. Vardiman's AcademicInfluence.com Rankings